BILL ANALYSIS                                                                                                                                                                                                    �



                                                                            



           ----------------------------------------------------------------- 
          |SENATE RULES COMMITTEE            |                        AJR 50|
          |Office of Senate Floor Analyses   |                              |
          |1020 N Street, Suite 524          |                              |
          |(916) 651-1520         Fax: (916) |                              |
          |327-4478                          |                              |
           ----------------------------------------------------------------- 
           
                                           
                                    THIRD READING


          Bill No:  AJR 50
          Author:   Bloom (D), et al.
          Amended:  8/21/14 in Assembly
          Vote:     21

           
           ASSEMBLY FLOOR  :  58-15, 8/21/14 - See last page for vote


           SUBJECT  :    Blood donation

           SOURCE  :     Equality California


           DIGEST  :    This resolution requests the President and the  
          Department of Health and Human Services (HHS) to adopt  
          science-based policies that repeal current Food and Drug  
          Administration (FDA) policies that prohibit men who have had sex  
          with men (MSM) from donating blood.

           ANALYSIS  :    This resolution makes the following legislative  
          findings:

          1.Declares that California law prohibits discrimination against  
            individuals on the basis of actual or perceived sex, sexual  
            orientation, gender identity, and gender-related appearance  
            and behavior. 

          2.Finds that current FDA policy effectively prohibits any man  
            who has had sex with another man even one time since 1977 from  
            donating blood for the rest of his life, and that the FDA  
            essentially classifies all sexually active gay and bisexual  
            men in the highest-risk blood donor category, the same  
                                                                CONTINUED





                                                                     AJR 50
                                                                     Page  
          2

            category as Intravenous drug users and people who have spent  
            more than five years since 1980 in a country that has mad cow  
            disease. 

          3.Declares that the American Red Cross, the American Association  
            for Blood Banks, and America's Blood Centers, at a 2006  
            workshop convened by the FDA, issued a joint statement that  
            they believe the current blood donation policy of lifetime  
            deferral for MSM is medically and scientifically unwarranted,  
            and calling for deferral criteria to be made comparable with  
            criteria for other groups at increased risk for sexual  
            transmission of infections that can be transmitted through  
            blood transfusion. 

          4.Asserts that it does not appear rational to broadly  
            differentiate sexual transmission via responsible male-to-male  
            sexual activity from transmission via responsible heterosexual  
            activity on scientific grounds, and that to many, this  
            differentiation is unfair, creates stigma without any  
            justifiable public health imperative, and fosters negative  
            attitudes towards blood collection facilities and the  
            eligibility criteria they use to screen donors. 

          5.Finds that many men who have sex with men are healthy, present  
            no risk of introducing HIV or other infectious agents into the  
            nation's blood supply, and wish to be blood donors without  
            compromising the safety or reliability of the blood supply. 

          6.States that FDA guidelines followed by blood banks throughout  
            the country inadvertently create unjustified stigma directed  
            towards MSM, and that these guidelines conflict with state  
            nondiscrimination policies. 

          7.Calls upon the President to encourage, and the Secretary of  
            HHS to adopt, policies that repeal current donor suitability  
            and deferral policies of the FDA prohibiting blood donation by  
            MSM, and instead direct the FDA to develop science-based  
            policies.

          This resolution requests the President and HHS to adopt  
          science-based policies that repeal current FDA policies that  
          prohibit MSM from donating blood.  

          Comments

                                                                CONTINUED





                                                                    AJR 50
                                                                     Page  
          3

           
          This resolution, sponsored by Equality California, respectfully  
          requests the President and HHS to adopt policies that repeal  
          current FDA policies that prohibit MSM from donating blood.  The  
          author believes that the current FDA policy is unnecessary given  
          improvements in donor screening techniques, and operates in an  
          unfair and discriminatory manner against homosexual men as a  
          group because of their status, without regard to whether  
          screening of individual donors indicates any risk of  
          transmitting disease via blood transfusion.  According to the  
          author, the FDA policy is "an outdated and discriminatory policy  
          that should be replaced scientific evidence-based practices for  
          collecting and testing donated blood."
           
          According to the FDA, MSM at any time since 1977 are deferred as  
          blood donors because, as a group, MSM are at increased risk for  
          HIV, hepatitis B, and other infections that can be transmitted  
          by blood transfusion.  The year 1977 was chosen because it  
          marked the beginning of the AIDS epidemic in the United States.   
          Although the FDA policy uses the term "deferral," the policy in  
          effect acts to prohibit, in all cases, MSM since 1977 from  
          donating blood. 

          The FDA has had a donor deferral policy for MSM since 1983, when  
          the risk of AIDS from transfusion was first recognized.  On  
          April 23, 1992, the FDA issued a memorandum (also known as a  
          "guidance document") to all blood donation establishments titled  
          Revised Recommendations for the Prevention of Human  
          Immunodeficiency Virus Transmission by Blood and Blood Products.  
           As is common in administrative law, the agency issued this  
          memorandum to those in the regulated community to provide  
          guidance and more detailed instruction on how to comply with  
          federal law and regulations. T he specific rules in such a  
          memorandum can and often do have the effect of agency policy.   
          In this case, the current FDA policy deferring blood donation by  
          MSM traces back to that 1992 memorandum and has remained in  
          effect since that time. 

          According to the FDA Internet Web site, the primary  
          responsibility of the agency is to enhance blood safety and  
          protect blood recipients, and its MSM deferral policy is  
          intended to protect all people who receive blood transfusions  
          from an increased risk of exposure to blood potentially infected  
          with certain disease-causing agents, including HIV, the virus  

                                                                CONTINUED





                                                                     AJR 50
                                                                     Page  
          4

          that causes AIDS.  The FDA cites a variety of epidemiological  
          and scientific data to justify its current MSM deferral policy,  
          including that:  (1) MSM since 1977 have an HIV prevalence 60  
          times higher than the general population and 800 times higher  
          than first time blood donors; (2) MSM account for the single  
          largest group of blood donors who are found HIV-positive by  
          blood donor testing; and (3) even the latest blood testing  
          technology cannot detect very low levels of HIV present in the  
          blood during the short "window period" right after infection but  
          before HIV tests can detect the virus.  The FDA has stated it  
          would change its MSM deferral policy "only if supported by  
          scientific data showing that a change in policy would not  
          present a significant and preventable risk to blood recipients."

          Under current FDA policy, potential blood donors judged to be at  
          risk for exposure via heterosexual routes are deferred for only  
          one year, while MSM with another man even once since 1977 are  
          permanently deferred.  The author believes the FDA is not  
          justified in broadly differentiating sexual transmission via  
          male-to-male sexual activity from that via heterosexual  
          activity.  As the measure states:  "Even with a clean bill of  
          health, a gay man is considered more of a threat to the blood  
          supply than a straight man who was treated for chlamydia,  
          syphilis, gonorrhea, venereal warts, and genital herpes within  
          the past year.  In 40 states, a man can even give blood  
          immediately following a tattoo or 12 months after having sex  
          with a prostitute."  Furthermore, the author contends that not  
          only do current FDA guidelines conflict with state  
          nondiscrimination policies, but they also may "inadvertently  
          create unjustified stigma directed towards gay, bisexual,  
          transgender, and heterosexual males on the basis that they have  
          had sex with another male since 1977."  According to comments  
          made by Dr. Ronald Bayer of Columbia University at the FDA  
          workshop in 2006, this threat of stigmatization is something  
          that has concerned gay advocates ever since the FDA first  
          implemented its lifetime deferral policy for MSM in 1983. 

          In summary, supporters of the resolution believe that the FDA  
          deferral policy is outdated and should be changed to reflect  
          accepted science about the safety of blood donated by MSM as  
          compared to other donor sources.  There is compelling evidence  
          to suggest that this is the case.  The resolution also  
          acknowledges social and political reasons that support changing  
          the FDA policy.  Proponents favor implementing a policy that  

                                                                CONTINUED





                                                                     AJR 50
                                                                     Page  
          5

          takes into account the individual risk factors associated with  
          the sexual activity of a potential donor, regardless of his  
          sexual orientation, and believe such a policy would reflect the  
          spirit, if not the letter, of state anti-discrimination law,  
          while reflecting sound scientific principles.  In addition, that  
          policy would presumably alleviate the fear of stigmatization,  
          long held by members of the gay community, associated with the  
          lifetime blood donation ban imposed on men who have sex with  
          other men.

           FISCAL EFFECT  :    Fiscal Com.:  No

           SUPPORT  :   (Verified  8/29/14)

          Equality California (source)
          Human Rights Campaign


           ASSEMBLY FLOOR  :  58-15, 8/21/14
          AYES:  Achadjian, Alejo, Ammiano, Bloom, Bocanegra, Bonilla,  
            Bonta, Bradford, Brown, Buchanan, Ian Calderon, Campos, Chau,  
            Chesbro, Cooley, Dababneh, Daly, Dickinson, Eggman, Fong,  
            Frazier, Garcia, Gatto, Gomez, Gonzalez, Gordon, Gray, Hall,  
            Roger Hern�ndez, Holden, Jones-Sawyer, Levine, Lowenthal,  
            Maienschein, Medina, Mullin, Muratsuchi, Nazarian, Nestande,  
            Pan, Perea, John A. P�rez, V. Manuel P�rez, Quirk,  
            Quirk-Silva, Rendon, Ridley-Thomas, Rodriguez, Salas, Skinner,  
            Stone, Ting, Weber, Wieckowski, Wilk, Williams, Yamada, Atkins
          NOES:  Allen, Ch�vez, Dahle, Donnelly, Fox, Gorell, Grove,  
            Hagman, Harkey, Mansoor, Melendez, Olsen, Patterson, Wagner,  
            Waldron
          NO VOTE RECORDED:  Bigelow, Conway, Beth Gaines, Jones, Linder,  
            Logue, Vacancy


          JL:k  8/29/14   Senate Floor Analyses 

                           SUPPORT/OPPOSITION:  SEE ABOVE

                                   ****  END  ****





                                                                CONTINUED





                                                                     AJR 50
                                                                     Page  
          6














































                                                                CONTINUED